Literature DB >> 2660897

The effect of reduced osmolarity on platinum drug toxicity.

E Smith1, A P Brock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2660897      PMCID： PMC2246727          DOI： 10.1038/bjc.1989.185

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  14 in total

1.  Cis-dichlorodiammineplatinum(II) in advanced bladder cancer.

Authors:  A Yagoda; R C Watson; J C Gonzalez-Vitale; H Grabstald; W F Whitmore
Journal:  Cancer Treat Rep       Date:  1976-07

2.  Combination chemotherapy with cis-dichlorodiammineplatinum(II) in disseminated testicular cancer.

Authors:  L H Einhorn
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

3.  The formation, identification, and significance of DNA-protein cross-links in mammalian cells.

Authors:  N L Oleinick; S M Chiu; N Ramakrishnan; L Y Xue
Journal:  Br J Cancer Suppl       Date:  1987-06

4.  Effects of low salt concentration on structural organization and template activity of chromatin in chicken erythrocyte nuclei.

Authors:  K Brasch; V L Seligy; G Setterfield
Journal:  Exp Cell Res       Date:  1971-03       Impact factor: 3.905

Review 5.  Review of the current clinical status of platinum coordination complexes in cancer chemotherapy.

Authors:  J A Gottlieb; B Drewinko
Journal:  Cancer Chemother Rep       Date:  1975 May-Jun

6.  Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration.

Authors:  C L Litterst
Journal:  Toxicol Appl Pharmacol       Date:  1981-10       Impact factor: 4.219

7.  Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat.

Authors:  R H Earhart; P A Martin; K D Tutsch; E Ertürk; R H Wheeler; F E Bull
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

8.  Nephrotoxicity of cis-dichlorodiammineplatinum(II).

Authors:  I H Krakoff
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

9.  Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry.

Authors:  B Rosenberg
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

Review 10.  Platinum nephrotoxicity.

Authors:  N E Madias; J T Harrington
Journal:  Am J Med       Date:  1978-08       Impact factor: 4.965
View more
  4 in total

Review 1.  Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.

Authors:  Loek A W de Jong; Fortuné M K Elekonawo; Philip R de Reuver; Andre J A Bremers; Johannes H W de Wilt; Frank G A Jansman; Rob Ter Heine; Nielka P van Erp
Journal:  Br J Clin Pharmacol       Date:  2018-10-25       Impact factor: 4.335

2.  Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.

Authors:  A Kondo; M Maeta; A Oka; S Tsujitani; M Ikeguchi; N Kaibara
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

3.  Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.

Authors:  Rosa Planells-Cases; Darius Lutter; Charlotte Guyader; Nora M Gerhards; Florian Ullrich; Deborah A Elger; Asli Kucukosmanoglu; Guotai Xu; Felizia K Voss; S Momsen Reincke; Tobias Stauber; Vincent A Blomen; Daniel J Vis; Lodewyk F Wessels; Thijn R Brummelkamp; Piet Borst; Sven Rottenberg; Thomas J Jentsch
Journal:  EMBO J       Date:  2015-11-03       Impact factor: 11.598

4.  The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).

Authors:  T Ohmori; T Morikage; Y Sugimoto; Y Fujiwara; K Kasahara; K Nishio; S Ohta; Y Sasaki; T Takahashi; N Saijo
Journal:  Jpn J Cancer Res       Date:  1993-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.